Diagnostic tool for Glanzmann\u27s thrombasthenia clinicopathologic spectrum by Ali, Natasha et al.
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
February 2008












See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Pathology Commons
Recommended Citation
Ali, N., Moiz, B., Shaikh, U., Adil, S., Rizvi, B., Rahman, Y. (2008). Diagnostic tool for Glanzmann's thrombasthenia clinicopathologic
spectrum. Journal of the College of Physicians and Surgeons Pakistan, 18(2), 91-4.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/16
Authors
Natasha Ali, Bushra Moiz, Usman Shaikh, Salman Adil, Bushra Rizvi, and Yasmeen Rahman
This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/16
Journal of The College of Physicians and Surgeons Pakistan  2008, Vol. 18 (2): 91-94 91
INTRODUCTION
Glanzmann’s thrombasthenia (GT) is a rare bleeding
diathesis, the mode of inheritance being autosomal
recessive.1 It affects the megakaryocyte lineage and is
marked by prolonged bleeding time, normal platelet
count and lack of platelet aggregation in response to all
platelet agonists except Risocetin.1 The disorder was
named after its discoverer who recognized this disease
in children from a Swiss Alps village in 1918.2
Although thrombasthenia is a rare disorder, it is being
found with increasing frequency in some regions of the
world where consanguinity is common, resulting in
increased expression of autosomal traits.3
Quantitative or qualitative defect of integrin alpha II b
beta 3 results in abnormal platelet aggregation as
seen in GT resulting in mucocutaneous bleeding.3
Platelet counts and functions that are not dependent on
this receptor complex are normal in patients with such
disorders. The varying degree of deficiency in this
platelet fibrinogen receptor gives rise to heterogeneity in
the severity of bleeding problem. Thus, patients with GT
can be classified into three types depending on their
integrin alpha II b beta 3 levels that may be markedly
low (< 5%) in type I, reduced (10-20%) in type II and
normal but dysfunctional in variant type.4 However,
before integrin alpha II b beta 3 abnormalities were
discovered, the original classification was based on
platelet fibrinogen binding and clot retraction.5
Purpura, epistaxis, gingival haemorrhage6 and
menorrhagia7 are the common manifestations in GT but
they can also present with life-threatening bleeding,
especially at the time of haemostatic challenges.
Acquired thrombasthenia due to glycoprotein IIb-IIIa
platelet antibodies has also been defined in a variety of
conditions.8
The common and well-established tools for screening
and diagnosing GT are platelet aggregation9 and flow
cytometry10 respectively. More specialized tests
(Western blotting, immunoprecipitation analysis and
gene sequencing) are generally reserved for reference
laboratories.11,12
The objective of the present study was to determine the
common clinical manifestations and laboratory findings
in patients with GT diagnosed through platelet
aggregometry.
ABSTRACT
Objective: To platelet aggregometry and describe the clinical spectrum of Glanzmann’s thrombasthenia diagnosed by
platelet aggregometry.
Study Design: A case-series.
Place and Duration of Study: This study was carried out at the clinical laboratories at the Aga Khan University Hospital,
Karachi from January 2003 to January 2006.
Patients and Methods: All patients irrespective of age and gender presenting with bleeding symptoms and having normal
platelet count were evaluated. Demographic details, relevant clinical history along with results of complete blood count,
bleeding time and platelet aggregation studies were retrieved through computerized data base and evaluated for the
diagnosis of Glanzmann’s thrombasthenia. 
Results: During the study period, 50 out of 2317 patients (2.2%)  were diagnosed as Glanzmann’s thrombasthenia by
platelet aggregometry with male to female ratio of 0.85:1 and median age of 10.2 years (ranging from 3 months to
27 years). Common symptoms were epistaxis, oral and gingival bleed, bleeding from minor cuts and trauma that were
observed in 46% of the patients; while 18%, 8% and 10% of them also complained of bruising, hematuria and bleeding
per rectum respectively. Majority i.e.  86% had a bleeding time greater than 10 minutes. All patients had received blood or
blood products for their bleeding episodes. 
Conclusion: Platelet aggregometry is a useful diagnostic modality for the assessment of Glanzmann’s thrombasthenia.
The disorder presents with muco-cutanoeus bleeding and was found to be a common cause of bleeding in our setup.
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PATIENTS AND METHODS
This was a cross-sectional observational study
conducted at  the Aga Khan University Hospital,
Karachi. All the patients referred to the clinical
laboratory with suspected inheritted platelet defects
based on clinical history and baseline screening tests
(normal platelet count and coagulation tests with
elevated bleeding time) were evaluated from January
2003 till January 2006. Detailed clinical history was
taken and physical examination was performed by a
doctor and findings were recorded on a pre-designed
proforma. Patients with thrombocytopenia or those who
had received platelet transfusions, aspirin, non-steroidal
anti inflammatory drugs and steroids, within ten days
prior to the aggregation studies, were excluded.13
Complete blood count (CBC) was performed on EDTA
blood through Coulter automated analyzer (Coulter
Electronics, Fullerton, CA, USA) and peripheral film was
also examined for each patient. Results of platelet count
were available for all 50 patients, however, red cell and
white cell parameters could be retrieved for only 26 patients
from the computerized system. Bleeding time was done by
Ivy’s method and the population based reference range
established in the laboratory was 1-6 minutes. 
Platelet aggregation tests were performed on Chronolog
Lumi Aggregometer (560 CA-Chronolog Corp,
Havertown, PA, USA) with reconstituted ristocetin,
adenosine 5-diphosphate (ADP), epinephrine barbate
and native collagen fibrils type1 from equine tendons
(Chrono-par® and chrono- lume® reagents) in the final
concentration of 1.25  mg/ml,10 µ M,  and 2µ g/ml
respectively. Reagent label and expiry dates were
checked for all agonists before use. Twelve ml of
patient’s blood sample was collected in two separate
tubes as follows:  nine ml in 3.2% sodium citrate in 9:1
ratio and 3 ml in K3 EDTA tube. Citrated sample was
centrifuged at 190 g for 15 minutes to prepare the
platelet rich plasma (PRP) and upper 2/3rd was
transferred to a separate tube while remaining sample
was hard spin at 10,000 g for 10 minutes to obtain
platelet poor plasma (PPP).14 The platelet count in PRP
was adjusted to 200-300 x 109 with the help of
autologous PPP after it was allowed to stand at room
temperature for 30 minutes. A sample from normal
subjects was treated similarly to prepare platelet rich
plasma and run simultaneously to serve as control. All
the assays were done within three hours of sample
collection and the manufacturer’s instructions were
strictly followed for conducting aggregation studies. The
aggregation was considered abnormal if it showed less
than 50% of increase in light transmission or absence
of secondary wave of aggregation.14
RESULTS
A total of 2317 patients with history of mucocutaneous
bleeding and suspected platelet function defects were
analyzed during the study period. GT was diagnosed on
the basis of platelet aggregometry when no or reduced
responses to various agonists except ristocetin were
observed. While on the contrary, those with only
Ristocetin defective responses and normal von
Willebrand assay were labeled as Bernard-Soulier
syndrome. Glanzmann’s thrombasthenia was the
most common platelet disorder and was observed in
50 patients while Bernard-Soulier syndrome was
diagnosed in 18 patients. The remaining 2249 patients
showed normal platelet aggregometry. There was case
of storage pool disease as secondary wave of
aggregation to ADP and collagen was present   in all of
those patients.
There were 23 males (46%) and 27 females (54%).
There was considerable heterogeneity in the age at
which these patients presented ranging from birth to 24
years with median of 10.2 and 13 (26%) patients below
the age of 5 years.
The most common clinical manifestations were bleeding
from mouth, gingival bleeds, epistaxis and bleeding from
minor cuts and trauma seen in 23(46%) patients. Nine
patients (18%) presented with bruising alone while few
others showed bleeding per rectum and hematuria
(Table I). There were 8 females  in the reproductive age
group, of whom 4 had frequent complaints of
menorrhagia. All 23 males were circumcised; however,
5 gave history of post circumcision bleeding. 
Fourteen patients (28%) gave positive family history of
bleeding while first cousin marriages among the parents
were observed in 7 patients (14%). History of red cell or
platelet transfusion at least once was observed in all
patients prior to diagnosis and, 27 (54%) had multiple
transfusions depending on their bleeding episodes.
Hemograms of the 26 patients (19 children, 3 adult
females and 4 adult males) showed that hemoglobin
levels were reduced in children and females with
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Table I:  Clinical details in our patients diagnosed as Glanzmann’s 
thrombasthenia  (n=50).
Clinical details in GT
Age at the time of presentation 0-24 years (median 3.5 years)
Age at the time of diagnosis 0.4-27 years (median10.2 years)
Sex 27 Females and 23 males
Epistaxis 18 patients
Petechiae/ecchymosis 14 patients
Gingival bleed 22 patients
Hematuria 04 patients
Rectal bleeding 05 patients
Post circumcision bleeding 05 patients
Menorrhagia 04 patients
Siblings with bleeding 14 patients
Consanguinity 07 patients
hypochromic microcytic indices (Table II). Leucocytosis
was characteristically observed in children. Platelet
counts of thrombasthenic patients (n= 50) ranged from
102 to 805 x 109/ l (mean 320) with subnormal values in
4 patients only. Examination of peripheral film did not
reveal any abnormality in platelet morphology in the
patients. Bleeding time was elevated to above 10
minutes in 43 patients (86%) while it was normal in 7
patients (14%). All patients with GT showed defective
platelet aggregometry in response to the agonists used
except ristocetin. 
DISCUSSION
Glanzmann’s thrombasthenia is a rare platelet function
disorder, which although has a worldwide distribution, is
concentrated in those areas where consanguinity is
common. Hence, ethnic groups like Iraqi Jews,15
Northern Iranis16 and Southern Indians17 have shown
high prevalence of this disorder. Similarly, in Pakistan
where intermarriages among families are quite a
common practice and accepted cultural norm, GT is not
rare as shown.  For the same reason, there was a
positive family history of bleeding in significant
proportion of those patients. 
Thirteen patients were younger than 5 years at the age
of diagnosis and this was similar to what has been
reported previously.18 The earlier diagnosis of GT is
very crucial for proper management of the disease,
hence, this platelet disorder should be considered in
every young patient who presents with mucocutaneous
bleeding or purpura, along with a normal platelet count
and elevated bleeding time. 
Epistaxis and gum bleeding were the commonest
clinical manifestations in our experience and was
observed in all age groups. This finding is supported by
others as well.19 Hematomas or hemarthroses are rare
manifestations of the disease,20 however, such soft
tissue swelling were not seen in any of our patients. A
frequent problem that afflicts thrombasthenic women is
menorrhagia, which affects 25-30% of them at some
stage during their reproductive age and even after in a
few.21 Correct diagnoses in such patients are essential
since menorrhagia itself is a debilitating condition.
Women with Glanzmann’s thrombasthenia in the
childbearing age often complain of this symptom and
patients included in this category of our study had
similar complaints.
Post-circumcision bleeding can be a devastating
problem in boys born with GT and it may require platelet
transfusions.22 Five of 23 circumscribed males in this
series had similar complaints. 
Of the 26 patients, 17 patients (2 females and 15
children) were anemic as revealed by their hemograms.
All these patients had hypochromic microcytic anemia,
which probably represent their chronic bleeds. This is a
common finding in GT patients consistent with the
severity of the disease. However, nutritional iron
deficiency anemia23 and beta thalassemia trait24 are
very common in our country and possibility of these as
co-existing etiologies could not be excluded. 
Most of the patients showed platelet and white cell
counts within normal range, however, leucocytosis was
observed in significant number of patients, especially
children group, that may be due to active bleeding or
infections. Bleeding time of more than 10 minutes was
present in 43 patients (86%). Although bleeding time is
an easily available tool for assessing in vitro platelet
functions; its high operator dependency, invasiveness
and lack of precision are the major obstacles in
providing meaningful results. PFA 100 is a better test in
this respect.25 However, lack of this instrument in the
set up restrained the researchers from such workup.
Moreso, definitive diagnosis of GT requires flow
cytometry and molecular studies like western blot and
gene sequencing; unfortunately, such sophisticated
technology is non-existent in Pakistan. 
Majority of the patients had been transfused with red
cells or platelets at least once before diagnosis was
made. The triggers for these transfusions were anemia
and bleeding episodes respectively. Over half of them
received repeated transfusions for their recurring
hemorrhage. Although management discussion was not
the scope of our paper, HLA typed platelets to avoid
iso immunization should be considered. For those
developing refractoriness to subsequent platelet
transfusions, recombinant factor VII is an available
option.26 However, none of these therapeutic options
were used in those patients before diagnosis was made.
CONCLUSION
Platelet aggregometry test is a useful adjunct for
diagnosis of Glanzmann’s thrombasthenia. There was a
2.2% frequency of thrombasthenia in the reported
series. The main symptoms were cutaneous and
mucosal bleeding. Majority of patients had normal
platelet count with elevated bleeding time which forms
the basis for screening for platelet dysfunction.
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Table II:   Hemogram, white cell count and bleeding time in our
patients (n=26).
Laboratory tests Results: Range (mean)
Adult males Adult females Children (<15)
n=4 n=3 n=19
Hemoglobin g/d 10.2 -13.6 (12.1) 5.6-11.6 (8.0) 4.5- 11.9(7.7)
MCV fl 77.5-79.2 (82.3) 66.6-77.6 (73.5) 54.3-68.3(67)
MCH pg 23.3-28.8 (26.2) 20.8-26.7 (23.7) 15.3-26.7 (21)
Total white cell
count x 109 5.6-12.5 (9.2) 4.4-10 (7.4) 5.6-32.3 (15.7)
MPV fl 8.4-13.2 (11) 9.7-9.9 (9.75) 6.8-17 (8.5)
Bleeding time (minutes) >10 >10 2-10 (10)*
* Median bleeding time is mentioned.
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